Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Currently many patients with a diagnosis of Giant Cell Arteritis (GCA) are on steroid therapy to help manage their disease. This study aims to explore the ability of biologic drug Kevzara to reduce the overall steroid exposure and help patients attain remission. Patients who have GCA and are interested in being a part of this study are invited to contact the study team to see if they qualify.
- Diagnosis of giant cell arteritis (GCA) according to European League Against Rheumatism/American College of Rheumatology classification criteria
- New onset active disease or refractory active disease
- At least one of the symptoms of GCA within 6 weeks of baseline
- Either erythrocyte sedimentation rate ≥30 mm/hour or C-reactive protein ≥10 mg/L within 6 weeks of baseline
- Receiving or able to receive prednisone 20-60 mg/day for the treatment of active GCA
Additional inclusion and exclusion criteria apply.
Keywordsgiant cell arteritis, GCA
Principal InvestigatorMichael R Bubb, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.